drugset / Trial / NCT02983734

D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)

NCT02983734

Phase 2 Unknown 56 enrolled Boston University Charles River Campus
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the efficacy of d-cycloserine (DCS) treatment for Gulf War Illness (GWI). Gulf War veterans with Gulf War Illness experience numerous chronic health symptoms, including cognition and fatigue, which reduces their quality of life. Gulf War veterans are in urgent need of novel treatment plans to tackle elusive symptomatology of Gulf War Illness. By using the literature of previous studies, the investigators have chosen to investigate d-cycloserine as a possible candidate for treating GWI, specifically cognitive symptoms. DCS has been shown to reduce neuroinflammation, regulate glutamate levels, and improve synaptic functioning in key areas of the brain.

Timeline

Start
2015-10
Primary completion
2019-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cycloserine Small molecule 100 mg Oral

Indications